Latest & greatest articles for nitroglycerin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nitroglycerin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nitroglycerin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nitroglycerin

1. Nitroglycerin

Nitroglycerin Top results for nitroglycerin - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for nitroglycerin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Efficacy of egg yolk and nitroglycerin ointment as treatments for acute anal fissures: A randomized clinical trial study. (PubMed)

Efficacy of egg yolk and nitroglycerin ointment as treatments for acute anal fissures: A randomized clinical trial study. Acute anal fissure as a common disease in society has several etiologies and manifestations such as severe anal pain and bleeding. Nitroglycerin ointment 0.2% is the most common topical treatment used. The most common side effect of nitroglycerin is headache, which is annoying for patients and often leads to discontinuation of the drug.Comparison of egg yolk as a natural (...) substance with analgesic and anti-inflammatory properties and minimal side effects with nitroglycerin ointment in the treatment of acute anal fissure.This randomized clinical trial was carried out during a 10-day period in the Gastroenterology clinic of Ghaem Hospital, Mashhad, Iran (year 2015). 126 patients who filled the inclusion criteria were enrolled. The patients were randomly divided into two groups. Nitroglycerin ointment (0.2%) was applied by patients in the first group, twice daily for 10 days

Full Text available with Trip Pro

2016 Electronic physician

3. Nitroglycerin for management of retained placenta. (PubMed)

Nitroglycerin for management of retained placenta. Retained placenta affects 0.5% to 3% of women following delivery, with considerable morbidity if left untreated. Use of nitroglycerin (NTG), either alone or in combination with uterotonics, may be of value to minimise the need for manual removal of the placenta in theatre under anaesthesia.To evaluate the benefits and harms of NTG as a tocolytic, either alone or in addition to uterotonics, in the management of retained placenta.We searched (...) and no differences were observed (mean difference (MD) -115.31, 95% CI -306.25 to 75.63; women = 169; I² = 83%). Nitroglycerin administration was not associated with an increase in headaches (RR 1.09, 95% CI 0.80 to 1.47; women = 174; studies = three; I² = 0%). However, nitroglycerin administration was associated with a significant, though mild, decrease in systolic and diastolic blood pressure and a significant increase in pulse rate (MD -3.75, 95% CI -7.47 to -0.03) for systolic blood pressure, and (MD 6.00

Full Text available with Trip Pro

2015 Cochrane

4. Nitroglycerin and Nitric Oxide - A Rondo of Themes in Cardiovascular Therapeutics. (PubMed)

Nitroglycerin and Nitric Oxide - A Rondo of Themes in Cardiovascular Therapeutics. 26510043 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Nitroglycerin and Nitric Oxide--A Rondo of Themes in Cardiovascular Therapeutics. 1789 10.1056/NEJMc1510178 Michel Thomas T Loscalzo Joseph J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Vasodilator Agents 31C4KY9ESH Nitric Oxide G59M7S0WS3 Nitroglycerin AIM IM N Engl J Med. 2015 (...) Jul 16;373(3):277-80 26176386 N Engl J Med. 2015 Oct 29;373(18):1788-9 26510044 Humans Nitric Oxide history Nitroglycerin history Vasodilator Agents history 2015 10 29 6 0 2015 10 29 6 0 2015 10 31 6 0 ppublish 26510043 10.1056/NEJMc1510178 10.1056/NEJMc1510178#SA2

Full Text available with Trip Pro

2015 NEJM

5. Nitroglycerin and Nitric Oxide - A Rondo of Themes in Cardiovascular Therapeutics. (PubMed)

Nitroglycerin and Nitric Oxide - A Rondo of Themes in Cardiovascular Therapeutics. 26510044 2015 10 30 2018 12 02 1533-4406 373 18 2015 10 29 The New England journal of medicine N. Engl. J. Med. Nitroglycerin and Nitric Oxide--A Rondo of Themes in Cardiovascular Therapeutics. 1788-9 10.1056/NEJMc1510178 Sauri Michael A MA eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Vasodilator Agents 31C4KY9ESH Nitric Oxide G59M7S0WS3 Nitroglycerin AIM IM N Engl J Med. 2015 Jul 16;373(3 (...) ):277-80 26176386 N Engl J Med. 2015 Oct 29;373(18):1789 26510043 Humans Nitric Oxide history Nitroglycerin history Vasodilator Agents history 2015 10 29 6 0 2015 10 29 6 0 2015 10 31 6 0 ppublish 26510044 10.1056/NEJMc1510178 10.1056/NEJMc1510178#SA1

Full Text available with Trip Pro

2015 NEJM

6. Topical Nitroglycerin for Peripheral Circulation and Wound Healing in the Elderly

Topical Nitroglycerin for Peripheral Circulation and Wound Healing in the Elderly Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Topical Nitroglycerin for Peripheral Circulation

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines

Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, or evidence-based guidelines were identified regarding the use

2014 Health Technology Assessment (HTA) Database.

8. Clevidipine compared with nitroglycerin for blood pressure control in coronary artery bypass grafting: a randomized double-blind study (PubMed)

Clevidipine compared with nitroglycerin for blood pressure control in coronary artery bypass grafting: a randomized double-blind study We tested the hypothesis that clevidipine, a rapidly acting dihydropyridine calcium channel blocker, is not inferior to nitroglycerin (NTG) in controlling blood pressure before cardiopulmonary bypass (CPB) during coronary artery bypass grafting (CABG).In this double-blind study from October 4, 2003 to April 26, 2004, 100 patients undergoing CABG with CPB were

2014 EvidenceUpdates

9. Nitroglycerin for the Treatment of Pulmonary Edema Following Submersion

Nitroglycerin for the Treatment of Pulmonary Edema Following Submersion TITLE: Nitroglycerin for the Treatment of Pulmonary Edema Following Submersion: Clinical Effectiveness and Guidelines DATE: 11 March 2014 RESEARCH QUESTIONS 1. What is the clinical effectiveness of nitroglycerin for the treatment of pulmonary edema secondary to submersion, in pre- or in-hospital settings? 2. What are the evidence-based guidelines regarding the use of nitroglycerin for the treatment of pulmonary edema (...) secondary to submersion, in pre- or in-hospital settings? KEY MESSAGE No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, or evidence-based guidelines were identified regarding the use of nitroglycerin for the treatment of pulmonary edema secondary to submersion in pre- or in-hospital settings. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 3

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Rectiv (nitroglycerin) Oinment

Rectiv (nitroglycerin) Oinment Drug Approval Package: Rectiv (nitroglycerin) NDA #021359 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Rectiv (nitroglycerin) Oinment 0.4% Company: ProStrakan, Inc. Application No.: 021359 Approval Date: 06/21/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2011 FDA - Drug Approval Package

11. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. (PubMed)

Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. Nitroglycerin stimulates bone formation and inhibits bone resorption, is inexpensive, and is widely available. Its effects on bone density, bone structure, and bone strength are unknown.To determine if nitroglycerin increases lumbar spine bone mineral density (BMD) and to evaluate changes in hip BMD, bone geometry, and density at the radius and tibia, and markers of bone turnover.A single (...) -center, double-blind, placebo-controlled randomized trial conducted in Toronto, Ontario, Canada, for 24 months starting in November 2005 and completed in March 2010, of 243 postmenopausal women with lumbar spine T scores of between 0 and -2.0 who completed a 1-week run-in period taking nitroglycerin ointment. Intervention Nitroglycerin ointment (15 mg/d) or placebo applied at bedtime for 24 months.Areal BMD at the lumbar spine, femoral neck, and total hip. Secondary outcomes included indices of bone

Full Text available with Trip Pro

2011 JAMA

12. Evidence on the effectiveness of topical nitroglycerin in the treatment of tendinopathies: a systematic review and meta-analysis (PubMed)

Evidence on the effectiveness of topical nitroglycerin in the treatment of tendinopathies: a systematic review and meta-analysis To evaluate evidence on the effectiveness of topical nitroglycerin (NTG) in treating tendinopathies.Systematic searches were conducted on ScienceDirect, Scirus, Highwire Press Stanford University, PubMed Central, Directory of Open Access Journals, Free Medical Journals, Free Full Text, Bioline International, Findarticles, BioMed Central, IndMed, OpenMD, QMed, Geneva

2010 EvidenceUpdates

13. Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis (PubMed)

Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis Acute pancreatitis after ERCP is a severe side effect.To evaluate the preventive effect of nitroglycerin on post-ERCP pancreatitis by a meta-analysis of randomized clinical studies.We searched on Pubmed, Embase, Cochrane Library and all abstracts presented at Digestive Disease Week and United European Gastrointestinal Week from 2004 to 2008. We used the MeSH terms 'pancreatitis' together (AND) with the terms: 'glyceryl (...) trinitrate', 'glyceryl dinitrate', 'isosorbide dinitrate' or 'nitroglycerin'.Five clinical studies evaluating the incidence of post-ERCP pancreatitis after administration of nitroglycerin were identified. Meta-analysis including all five studies showed a relative risk (RR) of 0.61 (95% CI; 0.44, 0.86) with the number needed to treat (NNT) of 26 (95% CI: 16, 82). Three studies evaluated nitroglycerin administered by a dermal patch reaching together an RR of 0.66 (95% CI; 0.43, 1.01). The use

Full Text available with Trip Pro

2009 EvidenceUpdates

14. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud`s phenomenon: A randomized, controlled trial (PubMed)

MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud`s phenomenon: A randomized, controlled trial Raynaud's phenomenon (RP) affects 3-9% of the general population and >90% of patients with systemic sclerosis. Nitrates are often prescribed for the treatment of RP, but currently available formulations are limited by side effects, particularly headaches, dizziness, and skin irritation. The purpose of this study was to evaluate the tolerability and efficacy of a novel (...) formulation of topical nitroglycerin, MQX-503, in the treatment of RP in an ambulatory setting.We conducted a multicenter, randomized, placebo-controlled study with a 2-week single-blind run-in period to determine baseline severity, followed by a 4-week double-blind treatment phase. Two hundred nineteen adult patients with a clinical diagnosis of primary or secondary RP received 0.9% MQX-503 gel or matching placebo during the treatment period. Gel was applied immediately before or within 5 minutes

Full Text available with Trip Pro

2009 EvidenceUpdates

15. Meta-analysis: nitroglycerin for prevention of post-ERCP pancreatitis

Meta-analysis: nitroglycerin for prevention of post-ERCP pancreatitis Meta-analysis: nitroglycerin for prevention of post-ERCP pancreatitis Meta-analysis: nitroglycerin for prevention of post-ERCP pancreatitis Bang UC, Nojgaard C, Andersen PK, Matzen P CRD summary This review supported nitroglycerin use for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis, but concluded that dermal administration did not show beneficial effects and required further (...) investigation. The authors' conclusions appear to reflect the evidence, but given several limitations with the included trials, including insufficient power and potential for bias in the review, the conclusions may not be reliable. Authors' objectives To assess the effectiveness of nitroglycerin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Searching MEDLINE, EMBASE, and the Cochrane Library were searched for relevant articles, and reference lists were handsearched

Full Text available with Trip Pro

2009 DARE.

16. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. (PubMed)

Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. The purpose of this study was to compare terbutaline and nitroglycerin for acute intrapartum fetal resuscitation.Women between 32-, 42 weeks' gestation were assigned randomly to 250 microg of terbutaline or 400 microg nitroglycerin intravenously for nonreassuring fetal heart rate tracings in labor. The rate of successful acute intrapartum fetal resuscitation and the maternal hemodynamic (...) changes were compared. Assuming a 50% failure rate in the terbutaline arm, we calculated that a total of 110 patients would be required to detect a 50% reduction in failure in the nitroglycerin group (50% to 25%), with an alpha value of .05, a beta value of .20, and a power of 80%.One hundred ten women had nonreassuring fetal heart rate tracings in labor; 57 women received terbutaline, and 53 women received nitroglycerin. Successful acute resuscitation rates were similar (terbutaline 71.9

2007 EvidenceUpdates

17. Chest pain relief by nitroglycerin does not predict active coronary artery disease. (PubMed)

Chest pain relief by nitroglycerin does not predict active coronary artery disease. The belief that chest pain relief with nitroglycerin indicates the presence of active coronary artery disease is common. However, this hypothesis has not been tested.To define the diagnostic and prognostic value of chest pain relief with nitroglycerin.Prospective observational cohort study.Urban community teaching hospital.459 consecutive patients with chest pain admitted through the emergency department who (...) received nitroglycerin from emergency services personnel or an emergency department nurse. Follow-up was obtained by telephone contact at 4 months.Chest pain relief was defined as a decrease of at least 50% in patients' self-reported pain within 5 minutes of the initial dose of sublingual or spray nitroglycerin. Active coronary artery disease was defined as any elevated serum enzyme levels, coronary angiography demonstrating a 70% or greater stenosis, or a positive exercise test result.Nitroglycerin

2003 Annals of Internal Medicine

18. Nitroglycerin in septic shock after intravascular volume resuscitation. (PubMed)

Nitroglycerin in septic shock after intravascular volume resuscitation. In patients with septic shock, oxygen consumption is increased, but oxygen delivery and extraction is impaired, partly because of microcirculatory shutdown and shunting. Orthogonal polarisation spectral (OPS) imaging allows visualisation of the microcirculation. We used this technique to assess microcirculatory flow in septic-shock patients who had a mean arterial blood pressure of more than 60 mm Hg and central venous (...) pressure greater than 12 mm Hg. The infusion of 0.5 mg of nitroglycerin intravenously then resulted in a marked increase in microvascular flow on OPS imaging. Improved recruitment of the microcirculation could be a new resuscitation endpoint in septic shock.

2002 Lancet

19. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. (PubMed)

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. Decompensated congestive heart failure (CHF) is the leading hospital discharge diagnosis in patients older than 65 years.To compare the efficacy and safety of intravenous nesiritide, intravenous nitroglycerin, and placebo.Randomized, double-blind trial of 489 inpatients with dyspnea at rest from decompensated CHF, including 246 who received pulmonary artery (...) catheterization, that was conducted at 55 community and academic hospitals between October 1999 and July 2000.Intravenous nesiritide (n = 204), intravenous nitroglycerin (n = 143), or placebo (n = 142) added to standard medications for 3 hours, followed by nesiritide (n = 278) or nitroglycerin (n = 216) added to standard medication for 24 hours.Change in pulmonary capillary wedge pressure (PCWP) among catheterized patients and patient self-evaluation of dyspnea at 3 hours after initiation of study drug among

2002 JAMA

20. Modelling the economic impact of managing a chronic anal fissure with a proprietary formulation of nitroglycerin (Rectogesic) compared to lateral internal sphincterotomy in the United Kingdom

Modelling the economic impact of managing a chronic anal fissure with a proprietary formulation of nitroglycerin (Rectogesic) compared to lateral internal sphincterotomy in the United Kingdom Modelling the economic impact of managing a chronic anal fissure with a proprietary formulation of nitroglycerin (Rectogesic) compared to lateral internal sphincterotomy in the United Kingdom Modelling the economic impact of managing a chronic anal fissure with a proprietary formulation of nitroglycerin (...) (Rectogesic) compared to lateral internal sphincterotomy in the United Kingdom Christie A, Guest J F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of nitroglycerin (0.2% glycerine nitrate, GTN) (Rectogesic) for the treatment

2002 NHS Economic Evaluation Database.